{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T22:51:21Z","timestamp":1648853481294},"reference-count":10,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,2,27]]},"DOI":"10.1182\/blood-2014-01-546705","type":"journal-article","created":{"date-parts":[[2014,2,27]],"date-time":"2014-02-27T17:38:02Z","timestamp":1393522682000},"page":"1284-1285","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Optimizing tolerability of TKI therapy in CML"],"prefix":"10.1182","volume":"123","author":[{"given":"Andreas","family":"Hochhaus","sequence":"first","affiliation":[{"name":"UNIVERSIT\u00c4TSKLINIKUM JENA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"9","key":"2019111819284809600_B1","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/blood-2013-07-513937","article-title":"Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.","volume":"123","author":"Kantarjian","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2019111819284809600_B2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia.","volume":"12","author":"O\u2019Hare","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"17","key":"2019111819284809600_B3","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"issue":"15","key":"2019111819284809600_B4","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure.","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"issue":"28","key":"2019111819284809600_B5","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111819284809600_B6","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111819284809600_B7","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"issue":"19","key":"2019111819284809600_B8","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111819284809600_B9","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111819284809600_B10","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-\u03b1 in newly diagnosed chronic myeloid leukemia.","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/123\/9\/1284\/1378970\/1284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/123\/9\/1284\/1378970\/1284.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:50:52Z","timestamp":1574124652000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/123\/9\/1284\/32931\/Optimizing-tolerability-of-TKI-therapy-in-CML"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,27]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,2,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-01-546705","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,27]]}}}